{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:09:19Z","timestamp":1758046159050,"version":"3.44.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Cardiologie et d'Ang\u00e9iologie"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ancard.2019.07.011","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T07:49:29Z","timestamp":1566892169000},"page":"347-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dur\u00e9e optimale de la double antiagr\u00e9gation plaquettaire apr\u00e8s angioplastie coronaire ou syndrome coronaire aigu. La personnalisation est-elle possible\u00a0?"],"prefix":"10.1016","volume":"68","author":[{"given":"J.L.","family":"Georges","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Cherif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ajlani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2012","series-title":"Bon usage des agents antiplaquettaires","author":"Agence national de s\u00e9curit\u00e9 des m\u00e9dicaments et produits de sant\u00e9","key":"10.1016\/j.ancard.2019.07.011_bib0255"},{"issue":"3","key":"10.1016\/j.ancard.2019.07.011_bib0260","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2019.07.011_bib0265","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018\u00a0ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2019.07.011_bib0270","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016\u00a0ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ancard.2019.07.011_bib0275","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jacc.2008.07.006","article-title":"Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study","volume":"52","author":"Wenaweser","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ancard.2019.07.011_bib0280","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/eurheartj\/ehs086","volume":"33","author":"Stefanini","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2019.07.011_bib0285","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ancard.2019.07.011_bib0290","first-page":"1034","article-title":"Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11,473\u00a0patients","volume":"38","author":"Palmerini","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2019.07.011_bib0295","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial","volume":"9","author":"Hong","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ancard.2019.07.011_bib0300","first-page":"e003145","article-title":"Six versus 12\u00a0months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2\u00a0trial","author":"Han","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ancard.2019.07.011_bib0305","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ancard.2019.07.011_bib0310","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ancard.2019.07.011_bib0315","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12928-015-0366-9","volume":"31","author":"Natsuaki","year":"2016","journal-title":"Cardiovasc Interv Ther"},{"key":"10.1016\/j.ancard.2019.07.011_bib0320","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-018-1392-2","article-title":"Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry","author":"Moalem","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ancard.2019.07.011_bib0325","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ancard.2019.07.011_bib0330","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ancard.2019.07.011_bib9320","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ancard.2019.07.011_bib0335","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jamacardio.2018.3551","article-title":"Efficacy and safety of drug-eluting stents optimized for biocompatibility vs bare-metal stents with a single month of dual antiplatelet therapy: a meta-analysis","volume":"3","author":"Shah","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ancard.2019.07.011_bib0340","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/archinternmed.2012.758","article-title":"Drug eluting vs. bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials","volume":"172","author":"De Luca","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ancard.2019.07.011_bib0345","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2019.07.011_bib0350","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ancard.2019.07.011_bib0355","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30\u00a0months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2019.07.011_bib0360","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1\u00a0year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ancard.2019.07.011_bib0365","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ancard.2019.07.011_bib0370","first-page":"365","article-title":"Stopping or continuing clopidogrel 12\u00a0months after drug-eluting stent placement: the OPTIDUAL randomized trial","volume":"37","author":"Helft","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2019.07.011_bib0375","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jcin.2017.04.019","article-title":"Dual antiplatelet therapy for 6\u00a0versus 18\u00a0months after biodegradable polymer drug-eluting stent implantation","volume":"10","author":"Nakamura","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ancard.2019.07.011_bib0380","doi-asserted-by":"crossref","unstructured":"Costa F, Van Klaveren D, Feres F, James S, R\u00e4ber L, Pilgrim T, et al. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J Am Coll Cardiol 73:741\u201354.","DOI":"10.1016\/j.jacc.2018.11.048"},{"key":"10.1016\/j.ancard.2019.07.011_bib0385","doi-asserted-by":"crossref","first-page":"e005849","DOI":"10.1161\/CIRCINTERVENTIONS.117.005849","article-title":"Benefit of prolonged dual antiplatelet therapy after implantation of drug-eluting stent for coronary bifurcation lesions: results from the Coronary Bifurcation Stenting Registry II","volume":"11","author":"Jang","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ancard.2019.07.011_bib0390","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.jcin.2018.09.020","article-title":"Dual antiplatelet therapy duration determines outcome after 2- but not 1-stent strategy in left main bifurcation percutaneous coronary intervention","volume":"11","author":"Rhee","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ancard.2019.07.011_bib0395","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ancard.2017.10.007","article-title":"Thrombose de stent\u00a0: quoi de neuf en 2017\u00a0?","volume":"66","author":"Kallel","year":"2017","journal-title":"Ann Cardiol Angeiol"},{"key":"10.1016\/j.ancard.2019.07.011_bib0400","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2019.07.011_bib0405","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ancard.2019.07.011_bib0410","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ancard.2019.07.011_bib0415","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2019.07.011_bib0420","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2019.07.011_bib0425","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6\u00a0vs. 12\u00a0months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2019.07.011_bib0430","doi-asserted-by":"crossref","first-page":"e0207386","DOI":"10.1371\/journal.pone.0207386","article-title":"Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome","volume":"13","author":"Jang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ancard.2019.07.011_bib0435","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ancard.2019.07.011_bib0440","first-page":"1220","article-title":"Twelve-month outcomes of patients unsuitable for prolonged DAPT presenting with an acute coronary syndrome and treated with polymer-free biolimus A9\u00a0drug-coated stents","volume":"92","author":"Kinnaird","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ancard.2019.07.011_bib0445","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 I inhibitor monotherapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ancard.2019.07.011_bib0450","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ahj.2019.02.015","article-title":"Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design. Ko YG, Choi D, Hong MK, Jang Y","volume":"212","author":"Kim","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.ancard.2019.07.011_bib0455","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijcard.2018.02.095","article-title":"Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: a meta-analysis of 11\u00a0randomized trials","volume":"264","author":"Verdoia","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ancard.2019.07.011_bib0460","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","article-title":"Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA2 (P-TIMI 50\u00a0trial)","volume":"380","author":"Scirica","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ancard.2019.07.011_bib0465","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2019.07.011_bib0470","first-page":"390","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials","volume":"37","author":"Udell","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2019.07.011_bib0475","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ancard.2019.07.011_bib0480","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1\u00a0year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ancard.2019.07.011_bib0485","first-page":"400","article-title":"Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54\u00a0trial","volume":"37","author":"Magnani","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2019.07.011_bib0490","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.12901018","article-title":"Duration of dual antiplatelet therapy in patients with CKD and drug-eluting stents: a meta-analysis","author":"Mavrakanas","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ancard.2019.07.011_bib0495","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ancard.2018.09.015","article-title":"Dur\u00e9e du traitement antiagr\u00e9gant plaquettaire chez le sujet \u00e2g\u00e9 stent\u00e9","volume":"67","author":"Sokoloff","year":"2018","journal-title":"Ann Cardiol Angeiol"},{"key":"10.1016\/j.ancard.2019.07.011_bib0250","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0038-1676545","article-title":"Racial differences in ischaemia\/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs","volume":"119","author":"Kang","year":"2019","journal-title":"Thromb Haemost"}],"container-title":["Annales de Cardiologie et d'Ang\u00e9iologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003392819300551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003392819300551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:36:55Z","timestamp":1757716615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003392819300551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0003392819300551"],"URL":"https:\/\/doi.org\/10.1016\/j.ancard.2019.07.011","relation":{},"ISSN":["0003-3928"],"issn-type":[{"type":"print","value":"0003-3928"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dur\u00e9e optimale de la double antiagr\u00e9gation plaquettaire apr\u00e8s angioplastie coronaire ou syndrome coronaire aigu. La personnalisation est-elle possible\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Annales de Cardiologie et d'Ang\u00e9iologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ancard.2019.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}